Gilead Sciences (GILD) EBITDA (2009 - 2026)
Gilead Sciences' (GILD) quarterly EBITDA came in at $2.6 billion in Q1 2026, up 15.6% YoY from $2.2 billion in Q1 2025, and up 30.34% on a QoQ basis from $2.0 billion in Q4 2025.
Gilead Sciences (GILD) EBITDA (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of EBITDA data on file, last reported at $2.6 billion in Q1 2026.
- Quarterly EBITDA rose 15.6% year-over-year to $2.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.4 billion (up 26.15% YoY) and the FY2025 annual result came in at $10.0 billion, up 503.01% from the prior year.
- EBITDA advanced to $2.6 billion in Q1 2026, from $2.0 billion in the prior quarter.
- In the past five years, EBITDA ranged from a high of $3.3 billion in Q3 2025 to a low of -$4.3 billion in Q1 2024.
- A 5-year average of $1.7 billion and a median of $2.2 billion in 2025 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2023 — EBITDA soared 765.48% — and 2024, when it plunged 353.49%.
- Tracing GILD's EBITDA over 5 years: stood at $2.3 billion in 2022, then slipped by 28.89% to $1.6 billion in 2023, then soared by 52.11% to $2.5 billion in 2024, then fell by 19.09% to $2.0 billion in 2025, then jumped by 30.34% to $2.6 billion in 2026.
- The last three EBITDA figures came in at $2.6 billion (Q1 2026), $2.0 billion (Q4 2025), and $3.3 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 7.14 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 6.43 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -584.00 Mn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 4.75 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 3.16 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 3.51 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -10.39 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 4.27 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 645.35 Mn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 16.77 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.39 Bn |
| Mar 31, 2026 | 2.59 Bn |
| Dec 31, 2025 | 1.98 Bn |
| Sep 30, 2025 | 3.33 Bn |
| Jun 30, 2025 | 2.47 Bn |
| Mar 31, 2025 | 2.24 Bn |
| Dec 31, 2024 | 2.45 Bn |
| Sep 30, 2024 | 888.00 Mn |
| Jun 30, 2024 | 2.64 Bn |
| Mar 31, 2024 | -4.32 Bn |
| Dec 31, 2023 | 1.61 Bn |
| Sep 30, 2023 | 2.62 Bn |
| Jun 30, 2023 | 1.67 Bn |
| Mar 31, 2023 | 1.71 Bn |
| Dec 31, 2022 | 2.27 Bn |
| Sep 30, 2022 | 2.84 Bn |
| Jun 30, 2022 | 2.03 Bn |
| Mar 31, 2022 | 197.00 Mn |
| Dec 31, 2021 | 940.00 Mn |
| Sep 30, 2021 | 3.84 Bn |